<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409721</url>
  </required_header>
  <id_info>
    <org_study_id>1204</org_study_id>
    <secondary_id>EB2006ALS</secondary_id>
    <nct_id>NCT00409721</nct_id>
  </id_info>
  <brief_title>The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effects of memantine in ALS patients using
      functional outcome measures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALS Functional Rating Scale-Revised (ALSFRS-R)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced vital capacity (FVC)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Manual Muscle Testing (MMT)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Addenbrooke Cognitive Examination (ACE)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor unit number estimates of hand and foot muscles</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-acetylaspartate in the motor cortex</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Memantine Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <arm_group_label>Memantine Low Dose</arm_group_label>
    <arm_group_label>Memantine High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  El Escorial Classification of laboratory supported probable, probable,or definite ALS

          -  Age 18 - 80 years,

          -  ALS symptoms for no more than 3 years,

          -  FVC greater than or equal to 60% predicted,

          -  Riluzole na√Øve or have been on a stable dose of Riluzole for at least 2 months,

          -  Patients must have the ability to attend monthly study visits in Edmonton or Calgary,
             Alberta

        Exclusion Criteria:

          -  Presence of significant sensory abnormalities, dementia, other neurologic diseases,
             uncompensated medical illness and psychiatric illness

          -  Female patients who are breastfeeding

          -  Use of concurrent investigational drugs,

          -  Patient unlikely to comply with study requirements

          -  Poor adherence to study protocol during run-in phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjay Kalra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Calgary ALS Neuromuscular Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta ALS Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ualberta.ca/als</url>
    <description>University of Alberta ALS Clinic</description>
  </link>
  <link>
    <url>http://www.alsa.org</url>
    <description>ALS Association of America (ALSA)</description>
  </link>
  <link>
    <url>http://www.alsab.ca/</url>
    <description>ALS Society of Alberta</description>
  </link>
  <link>
    <url>http://www.als.ca/</url>
    <description>ALS Society of Canada</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2006</study_first_submitted>
  <study_first_submitted_qc>December 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <last_update_submitted>March 1, 2011</last_update_submitted>
  <last_update_submitted_qc>March 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sanjay Kalra, MD</name_title>
    <organization>University of Alberta</organization>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>MND</keyword>
  <keyword>Memantine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

